The revision touches trade-margin-capped cancer medicines while expensive innovator brands remain untouched, exposing large hospital margins.

Lilly's tirzepatide franchise continues to expand, with Medicare Bridge contributing to the upside even as US drugmakers face pricing pressure.

Korea's first homegrown obesity treatment enters a three-way race with Novo Nordisk and Lilly products at a lower price point.

The head-to-head win strengthens Lilly's position in the incretin market race against Novo Nordisk.

The court questioned whether the pricing regulator NPPA has been ineffective, amid criticism that sharp cancer drug cuts expose excessive pricing.

Policymakers and experts debate how to cut medicine costs without undercutting domestic pharma investment.

The cell therapy developer reported underwhelming lung cancer results, with investors watching its melanoma program for direction.

US drugmakers reported strong results even as political pressure on medicine prices persists into the midterm season.

The company is looking to broaden its pipeline into brain disorders after building a dominant GLP-1 business.

Large-cap pharma earnings showed resilience across the sector in the latest reporting round.

Election outcomes could put pricing agreements between the White House and major drugmakers under congressional review.

New distribution channels and advertising disputes signal intensifying competition in the obesity drug market.

Analysts argue injectable device makers benefit from GLP-1 demand beyond a single-product bet.

Multinationals are broadening China activity from drug development into manufacturing.

The designation could bring expedited review and market incentives if the drug is approved.

The trial targets pulmonary arterial hypertension with an inhaled formulation.

Adjacent markets around GLP-1 use, from supplements to next-generation therapies, are expanding alongside the drugs themselves.

The clearance allows the company to expand clinical enrollment in the United States.